Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Study (n=623) found that this population treated with these agents developed multisystem immune-related adverse events, most commonly, pneumonitis thyroiditis, hepatitis thyroiditis, dermatitis pneumonitis, and dermatitis thyroiditis, which are associated with improved survival.

JAMA Oncology